Search results
Showing 101 to 150 of 1372 results for patients and public
Iptacopan for treating paroxysmal nocturnal haemoglobinuria [ID6176]
In development [GID-TA11132] Expected publication date: 26 June 2024
In development [GID-TA10165] Expected publication date: TBC
In development [GID-TA11369] Expected publication date: 14 August 2024
Zanubrutinib for treating relapsed or refractory marginal zone lymphoma [ID5085]
In development [GID-TA10962] Expected publication date: 17 July 2024
In development [GID-TA10505] Expected publication date: 12 June 2024
This quality standard covers care after emergency treatment for suspected anaphylaxis, including assessment and referral to specialist allergy services. It describes high-quality care in priority areas for improvement.
View quality statements for QS119Show all sections
Sections for QS119
- Quality statements
- Quality statement 1: Referral to specialist allergy services after emergency treatment
- Quality statement 2: Education in adrenaline auto-injector use
- Quality statement 3: Specialist assessment for venom immunotherapy
- Quality statement 4 (placeholder): Ongoing training in adrenaline auto-injector use
- Update information
- About this quality standard
In development [GID-TA10979] Expected publication date: 26 June 2024
In development [GID-TA10877] Expected publication date: 20 November 2024
Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]
In development [GID-TA11228] Expected publication date: 25 September 2024
In development [GID-TA11047] Expected publication date: 21 August 2024
Linzagolix for treating moderate to severe symptoms of uterine fibroids [ID6190]
In development [GID-TA11131] Expected publication date: TBC
Improving baseline assessment for newly diagnosed hypertensive patients and optimising therapy
investigations for newly diagnosed hypertensive patients are conducted at the point of diagnosis. Also to streamline the...
In development [GID-TA11418] Expected publication date: 14 August 2024
This quality standard covers support and treatment to stop smoking and stop using smokeless tobacco, and harm-reduction approaches for people who are not ready to stop in one go. It describes high-quality care in priority areas for improvement.
View quality statements for QS207Show all sections
Sections for QS207
- Quality statements
- Quality statement 1: Identifying people who use tobacco
- Quality statement 2: Advice
- Quality statement 3: Tobacco cessation support and treatment
- Quality statement 4: Harm-reduction approach
- Quality statement 5: Treatment to stop smoking in hospital
- Update information
- About this quality standard
There are a number of ways you can get involved in the development of our guidance.
Olipudase alfa for treating Niemann-Pick disease types A and B [ID3913 ]
In development [GID-HST10060] Expected publication date: TBC
Cabotegravir for preventing HIV-1 in adults and young people [ID6255]
In development [GID-TA11304] Expected publication date: 13 November 2024
Resources to help organisations who want to help develop NICE guidance
In development [GID-TA10611] Expected publication date: TBC
In development [GID-TA11390] Expected publication date: 24 July 2024
In development [GID-TA11197] Expected publication date: TBC
This quality standard covers diagnosing and managing common types of headache in adults and young people (aged 12 and over). It includes tension-type headache, migraine, cluster headache and medication overuse headache. It describes high-quality care in priority areas for improvement.
View quality statements for QS42Show all sections
Sections for QS42
- Quality statements
- Quality statement 1: Classification of headache type
- Quality statement 2: Preventing medication overuse headache
- Quality statement 3: Imaging
- Quality statement 4: Combined treatment for migraine
- Quality statement 5 (placeholder): Raising public and professional awareness
- Update information
- About this quality standard
This quality standard covers ways to reduce suicide and help people bereaved or affected by suicide. It describes high-quality care in priority areas for improvement.
View quality statements for QS189Show all sections
Sections for QS189
- Quality statements
- Quality statement 1: Multi-agency suicide prevention partnerships
- Quality statement 2: Reducing access to methods of suicide
- Quality statement 3: Media reporting
- Quality statement 4: Involving family, carers or friends
- Quality statement 5: Supporting people bereaved or affected by a suspected suicide
- Update information
- About this quality standard
Exagamglogene autotemcel for treating sickle cell disease [ID4016]
In development [GID-TA11249] Expected publication date: 17 July 2024
Fosdenopterin for treating molybdenum cofactor deficiency type A [ID6264]
In development [GID-HST10055] Expected publication date: 29 January 2025
Belzutifan for treating tumours associated with von Hippel-Lindau disease [ID3932]
In development [GID-TA10817] Expected publication date: TBC
In development [GID-TA11263] Expected publication date: TBC
We are listening to your views on this Diagnostics guidance. Comments close 26 April 2024.
In development [GID-TA10143] Expected publication date: TBC
In development [GID-TA11184] Expected publication date: TBC
Avapritinib for treating advanced systemic mastocytosis ID3770
In development [GID-TA11382] Expected publication date: TBC
This quality standard covers the mental wellbeing of older people (aged 65 and over) receiving care in care homes (including residential and nursing accommodation, day care and respite care). It focuses on support for people to improve their mental wellbeing so that they can stay as well and independent as possible. It describes high-quality care in priority areas for improvement.
View quality statements for QS50Show all sections
Sections for QS50
- Quality statements
- Quality statement 1: Participation in meaningful activity
- Quality statement 2: Personal identity
- Quality statement 3: Recognition of mental health conditions
- Quality statement 4: Recognition of sensory impairment
- Quality statement 5: Recognition of physical problems
- Quality statement 6: Access to healthcare services
- Update information
Find out more about quality standards advisory committee 3 members at NICE.
In development [GID-TA10999] Expected publication date: 21 August 2024
Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A [ID6170]
In development [GID-TA11106] Expected publication date: TBC
Erdafitinib for treating metastatic or unresectable FGFR-altered urothelial cancer [ID1333]
In development [GID-TA10252] Expected publication date: 29 January 2025
This guideline covers the components of a good experience of service use. It aims to make sure that all adults using NHS mental health services have the best possible experience of care.
This guideline covers how to identify adults at high risk of type 2 diabetes. It aims to remind practitioners that age is no barrier to being at high risk of, or developing, the condition. It also aims to help them provide those at high risk with an effective and appropriate intensive lifestyle-change programme to prevent or delay the onset of type 2 diabetes. The recommendations in this guideline can be used alongside the NHS Health Check programme .
This quality standard covers testing, diagnosing and managing hepatitis B in adults, young people and children (from birth). It describes high-quality care in priority areas for improvement.
View quality statements for QS65Show all sections
Sections for QS65
- Quality statements
- Quality statement 1: Testing and vaccination for hepatitis B
- Quality statement 2: Referral for specialist care
- Quality statement 3: Referral to and assessment by specialist care for pregnant women who are identified as hepatitis B surface antigen-positive at antenatal screening
- Quality statement 4: Complete course of neonatal hepatitis B vaccination and blood testing at 12 months
- Quality statement 5: Personalised care plan
- Quality statement 6: Monitoring people with chronic hepatitis B infection who do not meet the criteria for antiviral treatment
- Quality statement 7: 6-monthly surveillance testing for hepatocellular carcinoma in adults with chronic hepatitis B infection who have significant liver fibrosis or cirrhosis
This guideline aims to increase the uptake of all vaccines provided on the NHS routine UK immunisation schedule by everyone who is eligible. It supports the aims of the NHS Long Term Plan , which includes actions to improve immunisation coverage by GPs (including the changes to vaccinations and immunisations detailed in the 2021/2022 and 2022/23 GP contracts ) and support a narrowing of health inequalities.
In development [GID-TA11039] Expected publication date: 21 August 2024
In development [GID-TA11156] Expected publication date: 19 June 2024
Clostridioides difficile infection: antimicrobial prescribing (NG199)
This guideline sets out an antimicrobial prescribing strategy for managing Clostridioides difficile infection in adults, young people and children aged 72 hours and over in community and hospital settings. It aims to optimise antibiotic use and reduce antibiotic resistance. The recommendations do not cover diagnosis.
This quality standard covers assessing and managing borderline and antisocial personality disorders. It describes high-quality care in priority areas for improvement.
View quality statements for QS88Show all sections
Sections for QS88
- Introduction
- List of quality statements
- Quality statement 1: Structured clinical assessment
- Quality statement 2: Psychological therapies – borderline personality disorder
- Quality statement 3: Psychological therapies – antisocial personality disorder
- Quality statement 4: Pharmacological interventions
- Quality statement 5: Managing transitions
- Quality statement 6: Education and employment goals
This guideline covers managing hip fracture in adults. It aims to improve care from the time people aged 18 and over are admitted to hospital through to when they return to the community. Recommendations emphasise the importance of early surgery and coordinating care through a multidisciplinary Hip Fracture Programme to help people recover faster and regain their mobility.
This guideline covers how to make shared decision making part of everyday care in all healthcare settings. It promotes ways for healthcare professionals and people using services to work together to make decisions about treatment and care. It includes recommendations on training, communicating risks, benefits and consequences, using decision aids, and how to embed shared decision making in organisational culture and practices.
This guideline covers rehabilitation strategies for adults who have experienced a critical illness and stayed in critical care. It aims to improve physical, psychological and cognitive outcomes in people who have been discharged from critical care.
expenditure. You'll find this in the finance and workforce report section in our public board papers . Annual report . This includes our...
rapid assessment of flu product zanamivir. First public board meeting Register to attend a public board meeting . 2000...
In development [GID-TA11355] Expected publication date: 09 July 2024